Compared to the nicotine patch and a placebo, the smoking cessation drugs varenicline and bupropion do not show a significant increase in neuropsychiatric adverse events, researchers said.
"There are 1 billion smokers in the world and nearly 6 million smoking-related deaths each year, but there are only three approved medication treatments for quitting - nicotine replacement therapies like the patch and the two non-nicotine medications, bupropion and varenicline," said Robert Anthenelli from University of California.
The study is important because it prospectively examined the neuropsychiatric safety risks and quit-enhancing potential of the three medication classes versus placebo in a rigorous, adequately-sized, randomised controlled trial, Anthenelli said.
Researchers sought to directly assess the safety and efficacy of varenicline and bupropion compared to the nicotine patch and to a placebo in smokers with and without psychiatric disorders.
Also Read
It involved a randomised, controlled, double-blind trial examining more than 8,000 smokers seeking to quit in 16 countries over a period from November 2011 to January 2015.
"This is the first study to compare the safety and efficacy of the three first-line smoking cessation aids on the market, head-to-head, in smokers. It is the largest double-blind smoking cessation medication trial to date," said Anthenelli.
In terms of safety, approximately 2 per cent of non-psychiatric participants reported moderate or severe adverse neuropsychiatric events for any of the treatments, researchers said.
Specifically, it was 1.3 per cent for varenicline, 2.2 per cent for bupropion, 2.5 per cent for the nicotine patch and 2.4 per cent for placebo.
Anthenelli said the risk difference in the incidence of serious neuropsychiatric adverse events for varenicline and bupropion was not significantly higher than placebo - but that psychiatric patients trying to stop smoking are likely to have more confounding factors in treatment and appear to have a harder time quitting.
The findings were published in the journal The Lancet.